Dex as Analgesic Adjuvant in OSA Patients

• Status: Withdrawn
• Trial end date: 2015-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to assess whether intravenous peri-operative Dexmedetomidine reduces opioid requirements and or improves pain control after Uvulopalatopharyngoplasty (UPPP) in patients with obstructive sleep apnea (OSA).

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Montefiore Medical Center
• Treatments: Dexmedetomidine

Criteria

Inclusion Criteria:

• Age 18 or older

• Patients scheduled for UPPP

• Patients with diagnosis of OSA via polysomnography

• American Society of Anesthesiology (ASA) classification 3 or lower

Exclusion Criteria:

• Bradycardia as defined as resting heart rate <60 Beats per min (BPM) or symptomatic

• Any degree of heart block diagnosed by ECG

• Hypotension as defined as <20% from baseline or symptomatic

• Liver failure, (two fold rise in liver enzymes)

• Chronic Kidney Disease (CKD) III or greater

• History of allergy to opioids or dexmedetomidine

• ASA classification 4 or higher

• ICU or Step down admission

• Difficult airway as defined by previous history of difficult intubation or requiring a fiberoptic intubation.